TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28639533

Group type: EXPERIMENTAL
Intervention: Remifentanil (group R, n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nicardipine (group N, n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Remifentanil plus Nicardipine (group RN, n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nicardipine (group N)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Remifentanil plus Nicardipine (group RN)
Number of subjects: 45
Study: 25833714

Group type: COMPARATOR
Intervention: Task-sharing interventions delivered by trained and supervised non-specialist primary health care workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task-sharing counselling intervention for maternal depression delivered by non-specialist community health workers
Number of subjects: 0
Study: 24498516

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (NS)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (NS)
Number of subjects: 78
Study: 21816478

Group type: EXPERIMENTAL
Intervention: Clopidogrel resinate (75 mg) + aspirin (100 mg)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Clopidogrel bisulfate (75 mg) + aspirin (100 mg)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Clopidogrel resinate placebo + aspirin (100 mg)
Number of subjects: 314
Study: 19030021

Group type: EXPERIMENTAL
Intervention: 30 mg 6-month depot of leuprorelin acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 11.25 mg 3-month depot of leuprorelin acetate
Number of subjects: 0
Study: 17075347

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15331548

Group type: EXPERIMENTAL
Intervention: LoBAG diet (high-protein, low-carbohydrate diet)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet (carbohydrate:protein:fat ratio of 55:15:30)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LoBAG diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 8
Study: 11108568

Group type: EXPERIMENTAL
Intervention: Periurethral transurethral microwave thermotherapy (P-TUMT) using the TherMatrx TMx-2000 device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional transurethral microwave thermotherapy (TUMT)
Number of subjects: 0
Study: 9291903

Group type: COMPARATOR
Intervention: Single application of polidocanol 1%
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Single application of fibrin glue (FG)
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Daily repeated application of fibrin glue (FG)
Number of subjects: 854
Study: 8491905

Group type: EXPERIMENTAL
Intervention: FSE T2-weighted MRI
Number of subjects: 59

Group type: COMPARATOR
Intervention: CSE T2-weighted MRI
Number of subjects: 59

Group type: COMPARATOR
Intervention: CSE and FSE sequences
Number of subjects: 59
Study: 3113913

Group type: EXPERIMENTAL
Intervention: Buccal glyceryl trinitrate (Suscard)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sublingual glyceryl trinitrate (Nitromex)
Number of subjects: 126
Study: 29925851

Group type: EXPERIMENTAL
Intervention: PANSS items (delusions, suspiciousness, hallucinations, anxiety, excitement, tension, conceptual disorganization)
Number of subjects: 267
Study: 26661288

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5395

Group type: COMPARATOR
Intervention: Conventional therapy (enoxaparin followed by warfarin)
Number of subjects: 5395
Study: 24717254

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg administered at 10:30 pm
Number of subjects: 12
Study: 22381614

Group type: EXPERIMENTAL
Intervention: G-Bond Plus (1-SEA) applied with phosphoric-acid etching to enamel
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-Bond Plus (1-SEA) applied without phosphoric-acid etching to enamel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G-Bond Plus (1-SEA) applied to dentine using self-etch protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G-Bond Plus (1-SEA) applied to dentine using dry-bonding etch-and-rinse protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-Bond Plus (1-SEA) applied to dentine using wet-bonding etch-and-rinse protocol
Number of subjects: 0
Study: 21246841

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Western medication (Seretide inhalant)
Number of subjects: 36
Study: 18579976

Group type: EXPERIMENTAL
Intervention: 40 mg intravenous HBB
Number of subjects: 104

Group type: COMPARATOR
Intervention: 2 mL normal saline (Control)
Number of subjects: 104
Study: 17213783

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 53
Study: 12624556

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 1266
Study: 11118471

Group type: EXPERIMENTAL
Intervention: RPR 109881A at 52.5 mg/m(2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: RPR 109881A at 45 mg/m(2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: RPR 109881A
Number of subjects: 29
Study: 8886696

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 5 mg/day for 12 days during a 21-day cycle of transdermal estradiol (50 micrograms/day) for 6 cycles
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Medrogestone 5 mg/day for 12 days during a 21-day cycle of transdermal estradiol (50 micrograms/day) for 6 cycles
Number of subjects: 28
Study: 2000785

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase therapy
Number of subjects: 64
Study: 6313523

Group type: EXPERIMENTAL
Intervention: C + H (Captopril 25 mg t.i.d. + Hydrochlorothiazide 15 mg t.i.d.)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: C + H (Captopril 25 mg b.i.d. + Hydrochlorothiazide 25 mg b.i.d.)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: C + H (Captopril 50 mg b.i.d. + Hydrochlorothiazide 25 mg b.i.d.)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: H (Hydrochlorothiazide 15 mg t.i.d.)
Number of subjects: 625

Group type: COMPARATOR
Intervention: C (Captopril 25 mg t.i.d.)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study: 30958879

Group type: EXPERIMENTAL
Intervention: Activity impairment improvement with acute-phase treatment in STAR∗D (F = 7.27; df = 2,2625; P <. 001)
Number of subjects: 2697

Group type: EXPERIMENTAL
Intervention: Adding activity impairment variables to depression severity measures
Number of subjects: 2697

Group type: EXPERIMENTAL
Intervention: STAR∗D trial model estimates
Number of subjects: 2697
Study: 30055602

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo saline injections
Number of subjects: 288
Study: 27194304

Group type: EXPERIMENTAL
Intervention: EGCG+RES (282 mg EGCG and 80 mg RES per day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: EGCG+RES
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 24287639

Group type: EXPERIMENTAL
Intervention: Endoscopic papillary balloon dilation (EPBD)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Endoscopic biliary sphincterotomy (EBS)
Number of subjects: 132
Study: 22801453

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 19460913

Group type: EXPERIMENTAL
Intervention: Structured care (n = 104)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Patients attaining >=3 treatment targets (n = 91)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care (n = 101)
Number of subjects: 205
Study: 17396158

Group type: EXPERIMENTAL
Intervention: Dietary soy protein
Number of subjects: 0
Study: 15529620

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11450676

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone, 2 g daily for 30 days, followed by oral doxycycline, 200 mg daily for 60 days
Number of subjects: 129

Group type: COMPARATOR
Intervention: Matching intravenous and oral placebos
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone and oral doxycycline
Number of subjects: 129
Study: 10696354

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study: 7982727

Group type: EXPERIMENTAL
Intervention: Laparotomy for adhesiolysis
Number of subjects: 89

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Biopsies from adhesions and sactosalpinx
Number of subjects: 89
Study: 3059456

Group type: EXPERIMENTAL
Intervention: Very detailed follow-up programme
Number of subjects: 600

Group type: COMPARATOR
Intervention: Virtually no follow-up
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Repeated polypectomy
Number of subjects: 600
Study: 29985281

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d) administered preoperatively for 5-7 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control treatment group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MiR-15a-5p mimic in cardiomyocytes
Number of subjects: 70
Study: 27769054

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/cisplatin followed by surgery (CS)
Number of subjects: 281
Study: 25620765

Group type: EXPERIMENTAL
Intervention: Paravertebral blockade with 0.5% bupivicaine before induction of general anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paravertebral blockade with 0.5% bupivicaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paravertebral blockade
Number of subjects: 60
Study: 23433590

Group type: EXPERIMENTAL
Intervention: Nevirapine (200 mg twice daily)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Efavirenz (600 mg once daily)
Number of subjects: 285
Study: 20515559

Group type: EXPERIMENTAL
Intervention: Gaviscon Liquid (peppermint)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action Liquid (peppermint)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gaviscon Powder Formulation (fresh tropical)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-active sublingual control
Number of subjects: 45
Study: 18455221

Group type: COMPARATOR
Intervention: Fixed-dose budesonide/formoterol (160/4.5 microg x 2 inhalations twice daily)
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Adjustable-dose budesonide/formoterol (adjustable from 2 inhalations [320/9 microg] twice daily to 2 inhalations [320/9 microg] once daily or 4 inhalations [640/18 microg] twice daily)
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Fixed-dose fluticasone propionate/salmeterol (250/50 microg x 1 inhalation twice daily)
Number of subjects: 1225
Study: 17201838

Group type: EXPERIMENTAL
Intervention: Selective HB pacing (SHBP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: para-Hisian pacing (PHP)
Number of subjects: 17
Study: 12747273

Group type: EXPERIMENTAL
Intervention: Diclofenac hydroxyethylpyrrolidine (DHEP) patch
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 10905443

Group type: EXPERIMENTAL
Intervention: Computer-assisted screw application using an optoelectronic navigation system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional pedicle screw placement
Number of subjects: 100
Study: 8853276

Group type: EXPERIMENTAL
Intervention: T20 (20 degrees C and 20% RH)
Number of subjects: 7

Group type: COMPARATOR
Intervention: T3 (3 degrees C and approximately 50% RH)
Number of subjects: 7
Study: 1320133

Group type: EXPERIMENTAL
Intervention: Nonoxynol 9 sponge
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 6389648

Group type: EXPERIMENTAL
Intervention: aqueous mixed-grass extract
Number of subjects: 45

Group type: COMPARATOR
Intervention: allergoid mixed-grass extract
Number of subjects: 45

Group type: COMPARATOR
Intervention: histamine placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: aqueous mixed-grass extract, allergoid, histamine placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: allergoid grass extract
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LNIT
Number of subjects: 45
Study: 31010102

Group type: EXPERIMENTAL
Intervention: Healthy Mom Zone intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 29544162

Group type: EXPERIMENTAL
Intervention: Adjuvant zoledronic acid (ZOL) 4 mg administered by intravenous infusion every 3-4 weeks for 6 doses, then 3 monthly × 8 and 6 monthly × 5 for 5 years.
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Adjuvant zoledronic acid (ZOL)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control arm (standard therapy)
Number of subjects: 244
Study: 26677940

Group type: EXPERIMENTAL
Intervention: C-Tb
Number of subjects: 253

Group type: COMPARATOR
Intervention: QFT-GIT
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: C-Tb in HIV-infected patients
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: C-Tb in HIV-uninfected patients
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: C-Tb and QFT-GIT combined
Number of subjects: 253
Study: 25069559

Group type: EXPERIMENTAL
Intervention: Questioning-training by providing prompts (G1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Question-generation without any explicit instruction (G2)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No question control (G3)
Number of subjects: 72
Study: 22174346

Group type: EXPERIMENTAL
Intervention: Propofol-dexmedetomidine (Group PD)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Propofol-remifentanil (Group PR)
Number of subjects: 72
Study: 20814780

Group type: EXPERIMENTAL
Intervention: Limited portal carpal tunnel release
Number of subjects: 161

Group type: COMPARATOR
Intervention: Classic open release
Number of subjects: 161
Study: 18609474

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC) dosed twice daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Latanoprost dosed every evening
Number of subjects: 31

Group type: COMPARATOR
Intervention: Timolol run-in
Number of subjects: 31
Study: 16268183

Group type: EXPERIMENTAL
Intervention: Montelukast plus beclomethasone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgery-montelukast-beclomethasone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy (Group 2)
Number of subjects: 30
Study: 12045163

Group type: EXPERIMENTAL
Intervention: Baseline C-reactive protein (CRP) levels
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CRP levels (highest quartile)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Homocysteine and lipid levels
Number of subjects: 97
Study: 9887649

Group type: EXPERIMENTAL
Intervention: Educational videotape
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine educational care (Control)
Number of subjects: 62
Study: 7872219

Group type: EXPERIMENTAL
Intervention: Red wine (400 mL/d for 2 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: White wine (400 mL/d for 2 weeks)
Number of subjects: 17
Study: 2205329

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: iopromide
Number of subjects: 101
Study: 629844

Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (20 mg/kg/day for 3 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thiabendazole
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 30056562

Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Oral Iron
Number of subjects: 191

Group type: COMPARATOR
Intervention: Any IV Iron
Number of subjects: 191

Group type: COMPARATOR
Intervention: Iron Sucrose
Number of subjects: 191
Study: 29126461

Group type: EXPERIMENTAL
Intervention: Deferred recruitment model
Number of subjects: 171
Study: 26451731

Group type: EXPERIMENTAL
Intervention: Sport participation
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Community social capital
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Individual social capital
Number of subjects: 414
Study: 23916928

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (2 g/day), vitamin C (1 g/day), and vitamin E (400 IU/day)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids plus vitamins C and E supplementation
Number of subjects: 203
Study: 21802920

Group type: EXPERIMENTAL
Intervention: EGb 761 (240 mg once daily)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 19009173

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 202

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 202
Study: 17286569

Group type: EXPERIMENTAL
Intervention: ATP injection during intravenous isoproterenol infusion (ISP-infusion) after successful extensive encircling pulmonary vein isolation (EEPVI)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ATP injection
Number of subjects: 82

Group type: COMPARATOR
Intervention: Previous EEPVI without ATP injection
Number of subjects: 82
Study: 14556451

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11009237

Group type: EXPERIMENTAL
Intervention: 1.73% lidocaine with ketorolac (4 mg/mL)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1.73% lidocaine
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1.73% lidocaine plus intravenous ketorolac (20 mg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1.73% lidocaine with .67% ethanol
Number of subjects: 79
Study: 8883419

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 12
Study: 1499443

Group type: EXPERIMENTAL
Intervention: Cold stress (4 degrees C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control stimulus (37 degrees C)
Number of subjects: 9
Study: 3974051

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31924316

Group type: EXPERIMENTAL
Intervention: Chemotherapy with docetaxel and prednisone administered every 3 weeks for six cycles
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard of care (SOC) with observation
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Chemotherapy with docetaxel and prednisone
Number of subjects: 298
Study: 29803638

Group type: EXPERIMENTAL
Intervention: CSE-1034 (3g every 12h)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ceftriaxone (2g every 12h)
Number of subjects: 93
Study: 26241775

Group type: EXPERIMENTAL
Intervention: MEDIC‐treatment (neuromuscular exercise, education, diet, insoles, pain medication)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (two leaflets with information and treatment advice)
Number of subjects: 100
Study: 24879797

Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine (n=495)
Number of subjects: 991

Group type: COMPARATOR
Intervention: lapatinib plus capecitabine (n=496)
Number of subjects: 991
Study: 22434618

Group type: EXPERIMENTAL
Intervention: Enhanced follow-up
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 42
Study: 20188239

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 16
Study: 18219836

Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI (90 microg; 2 actuations of 45 microg; n = 496)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Racemic albuterol HFA MDI (180 microg; 2 actuations of 90 microg; n = 250)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI
Number of subjects: 746

Group type: COMPARATOR
Intervention: Racemic albuterol HFA MDI
Number of subjects: 746
Study: 16148283

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg daily)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study: 11812271

Group type: EXPERIMENTAL
Intervention: Oral/metered-dose inhaler (oral/MDI) regimen
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous/nebulizer (I.V./neb) regimen
Number of subjects: 34
Study: 10351966

Group type: EXPERIMENTAL
Intervention: Cocaine use within the 60 minutes preceding the onset of myocardial infarction symptoms
Number of subjects: 3946

Group type: COMPARATOR
Intervention: Nonusers of cocaine
Number of subjects: 3946
Study: 8557001

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (0.3 mg kg‐1 ED95)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Number of subjects: 0
Study: 1834391

Group type: EXPERIMENTAL
Intervention: ANF 4.5 micrograms/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ANF 2.0 micrograms/kg
Number of subjects: 12
Study: 7094971

Group type: EXPERIMENTAL
Intervention: Clomipramine (C1) at 75 mg per day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clomipramine (C1) at increasing dosage up to 150 mg per day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clomipramine (C1)
Number of subjects: 31
Study: 31833552

Group type: EXPERIMENTAL
Intervention: Grafted scars
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ungrafted scars
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy skin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Grafted flame burn scars
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Grafted and ungrafted scars
Number of subjects: 19
Study: 30841505

Group type: EXPERIMENTAL
Intervention: Actual plant
Number of subjects: 23

Group type: COMPARATOR
Intervention: Artificial plant
Number of subjects: 23

Group type: COMPARATOR
Intervention: Photograph of a plant
Number of subjects: 23

Group type: COMPARATOR
Intervention: No plant
Number of subjects: 23
Study: 28782266

Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Naloxegol 37.5 mg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185